IN VITRO DIAGNOSTICS AltheaDx Inc. AltheaDx 's Series C brings in $30mm AltheaDx Inc. (oncology R&D services and personalized medicine focused on cardio, neuro, and blood disorders) brought in
Financings During the third quarter of 2012, biopharma financings jumped to just over $3 billion, a 13% increase over the Q2 total. Heading the list was small-molecule cancer therapeutics developer
IN VITRO DIAGNOSTICS Mergers & Acquisitions Life Technologies Corp. Navigenics Inc. In an initial move to build up its molecular diagnostics business, Life Technologies Corp. is buying privately h